Br J Cancer: Feasibility analysis of diagnostic biopsy in patients with advanced hepatocellular carcinoma

As early as 2001, the European Association for the Study of the Liver (EASL) first defined the Non-Invasive Radiology Criteria (NIRC) for the diagnosis of hepatocellular carcinoma (HCC), and continued to improve the criteria over time
.

Most of the current studies investigating the diagnostic accuracy of NIRC are retrospective studies, focusing on the detection of early disease

As early as 2001, the European Association for the Study of the Liver (EASL) first defined the Non-Invasive Radiology Criteria (NIRC) for the diagnosis of hepatocellular carcinoma (HCC), and continued to improve the criteria over time

In November 2017, the NHS in the United Kingdom required histological confirmation of HCC before starting treatment with the drug sorafenib
.

It also allows for multi-center, prospective audits to better identify the safety and results of biopsy in patients with advanced HCC

The study is a prospective multi-center review study, and at a multidisciplinary meeting, patients who are suitable for sorafenib treatment have been identified
.

Researchers collected relevant clinical, radiological and histological data and compiled them into standardized case report forms

The results showed that the researchers collected a total of 418 cases from 11 centers, of which 361 were the main analysis cohort (PAC)
.

Overall, 76% of patients have chronic liver disease, and 66% of patients have cirrhosis

Forty-five patients had histological examination data, 270 patients underwent a new biopsy, and 93.

4% of them were diagnosed with HCC

Research flow chart

Research flow chart

All in all, the results of the study reveal that diagnostic biopsy is safe and feasible for most patients eligible for systemic treatment
.

The results of the study revealed that diagnostic biopsy is safe and feasible for most patients eligible for systemic treatment
.

The results of the study revealed that diagnostic biopsy is safe and feasible for most patients eligible for systemic treatment

Biopsy for advanced hepatocellular carcinoma: results of a multicentre UK audit

 

Leave a message here